Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Novartis Venture Fund
AddedFeb 13, 2024
UpdatedJun 28, 2026
Novartis Venture Fund

Novartis Venture Fund

Operating

Venture capital firm specializing in the development and investment of innovative therapeutics.

Location
Basel, Basel-Stadt, CH
Founded
1996
Firm
Compare
Portfolio
Employees
Website

Investments

Hyku
Hyku

Total Raised

$56M

Rounds

1

Seed$56MSeptember 2023
Fore Biotherapeutics
Fore Biotherapeutics

Total Raised

$166.5M

Rounds

9

Series D$75MAugust 2023
Series C$57MSeptember 2020
Mediar Therapeutics
Mediar Therapeutics

Total Raised

$145.6M

Rounds

4

Series A$85MMarch 2023
Capstan Therapeutics
Capstan Therapeutics

Total Raised

$165M

Rounds

2

Series A$102MSeptember 2022
Seed$63MNovember 2021
Immpact Bio
Immpact Bio

Total Raised

$129M

Rounds

2

Series B$111MJanuary 2022
Series A$18MAugust 2020
Exo Therapeutics
Exo Therapeutics

Total Raised

$103M

Rounds

2

Series B$78MOctober 2021
Series A$25MDecember 2020
Expansion Therapeutics
Expansion Therapeutics

Total Raised

$142.2M

Rounds

3

Series B$80MSeptember 2021
Flywheel
Flywheel

Total Raised

$105.3M

Rounds

6

Series C$27MSeptember 2021
Immunitas Therapeutics
Immunitas Therapeutics

Total Raised

$97M

Rounds

2

Series B$58MAugust 2021
GentiBio
GentiBio

Total Raised

$177M

Rounds

2

Series A$157MAugust 2021
Seed$20MAugust 2020
Ribon Therapeutics
Ribon Therapeutics

Total Raised

$259M

Rounds

7

Series C$65MJune 2021
Series B$65MJanuary 2019
Soteria Biotherapeutics
Soteria Biotherapeutics

Total Raised

$42M

Rounds

1

Series A$42MMay 2021
TScan Therapeutics
TScan Therapeutics
Public

Total Raised

$197.5M

Rounds

6

Series C$100MJanuary 2021
Series B$35MJanuary 2020
Series BJuly 2019
Faze Medicines
Faze Medicines

Total Raised

$81M

Rounds

1

Series A$81MDecember 2020
Escape Bio
Escape Bio

Total Raised

$187.1M

Rounds

4

Series Unknown$73MSeptember 2020
Cala Health
Cala Health

Total Raised

$148.3M

Rounds

4

Series C$50MMay 2019
Twentyeight-Seven Therapeutics
Twentyeight-Seven Therapeutics

Total Raised

$80M

Rounds

3

Series A$15MMay 2019